Acknowledgements This study is supported, in part, by the University of Kansas Medical Center Endowment Fund, and by research grants from Shenzhen Key Laboratory of Steroid Drug Discovery and Development (grant # ZDSYS20190902093417963) and the National Natural Science Foundation of China (grant # 81630096)
Provides intense hydration to the skin
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Watch for headaches, feeling shaky or confused, sweating, vague vision, or your heart racing
Tesamorelin is FDA-indicated for reducing excess abdominal fat in HIV-associated lipodystrophy, and the label states it is not indicated for weight loss management
The Glucagon Paradox in Next-Generation Incretin Therapy: How GLP-1, GIP, and Glucagon Receptor Co-Agonism May Amplify Weight Loss Despite Glucagons Hyperglycemic Biology Abstract The development of dual and triple incretin-based receptor agonists represents a major advance in the pharmacologic treatment of obesity, type 2 diabetes, and related cardiometabolic disease